Stephen Ray Mitchell - Jun 15, 2021 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
Director
Signature
/s/ Stephen Ray Mitchell
Stock symbol
VNDA
Transactions as of
Jun 15, 2021
Transactions value $
-$54,683
Form type
4
Date filed
6/17/2021, 05:01 PM
Previous filing
Jun 14, 2021
Next filing
Sep 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $42.4K +4.02K +39.36% $10.57 14.2K Jun 15, 2021 Direct
transaction VNDA Common Stock Sale -$97.1K -5K -35.17% $19.42 9.22K Jun 15, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Stock Option (right to buy) Options Exercise $0 -4.02K -40.15% $0.00 5.99K Jun 15, 2021 Common Stock 4.02K $10.57 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 A portion of the shares was sold to satisfy the exercise price of the stock option and the tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021.